Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution

BACKGROUND: With the rapid influx of novel anti‐cancer agents, phase I clinical trials in oncology are evolving. Historically, response rates on early phase trials have been modest with the clinical benefit and ethics of enrolment debated. However, there is a paucity of real‐world data in this setti...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Siddharth, Davies, Amy, Frentzas, Sophia, Hawkins, Cheryl‐Ann, Segelov, Eva, Day, Daphne, Markman, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842700/
https://www.ncbi.nlm.nih.gov/pubmed/34245134
http://dx.doi.org/10.1002/cnr2.1465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842700/
https://www.ncbi.nlm.nih.gov/pubmed/34245134
http://dx.doi.org/10.1002/cnr2.1465

Ejemplares similares